The forum, which took place Aug. 19, focused on the impact that research funded by the National Institutes of Health makes on the Kansas City area. The panel included individuals from NIH-funded institutions, local entrepreneurial companies and patients that are directly benefitting from NIH research.
Dr. Joyce has 28 years of research experience, including 15 in administrative roles. He is an internationally known researcher and pharmaceutical consultant in central nervous system drug discovery, and his work has led to target development for drug discovery in both schizophrenia and Parkinson’s disease. At KCUMB, Dr. Joyce is tasked primarily with helping the University achieve its strategic goal of enhancing research activity.
Along with Dr. Joyce, panelists included: Steve O’Connor, chief executive officer for ImpeDx Diagnostics, Inc.; Douglas Girod, M.D., executive vice chancellor of the University of Kansas Medical Center; Scott Weir, Pharm.D., Ph.D., director of the Institute for Advancing Medical Innovation at the University of Kansas; and Leesa Gabel, a cancer survivor and volunteer with the Livestrong Foundation.